LifeOmic and XCure team up to identify better cancer treatment options

We’re excited to bring Transform 2022 back to life on July 19th and virtually July 20-28. Join AI and data leaders for sensible conversations and exciting networking opportunities. Register today!


LifeOmic, an precision health platform, and XCures, which helps identify cancer treatment options, have partnered to streamline and improve recommendations for cancer care. The companies say the partnership aims to increase accuracy and efficiency in reviewing and analyzing medical documents, which is crucial for creating medical digital twins to generate data for AI analysis and find results from a variety of treatment options.

This partnership in cancer research is designed to integrate XCures’ tools with LifeOmic’s Precision Health Cloud to mean data from health records, medical devices, consumer health and new genomics technology. It supports applications for individuals, employers, healthcare organizations and pharmaceutical companies. It has also developed OCR tools that can automate the process of digitizing and analyzing paper and written records.

How technology helps identify more promising treatment options

XCures uses artificial intelligence (AI) and predictive modeling to identify and rank the most promising treatment options for advanced cancer patients who do not respond to care therapy standards. XCures make it possible to learn from the experiences of all patients who provide their data in exchange for treatment options and optimize the choice of options for future patients.

XCures Tech analyzes each patient’s data as a resource to create a cancer history and snapshots of what happened with the patient’s clinical care path. This platform distorts essential patient information about cancer presented as a time series like the Ghent chart.

This helps report software that acts like a referral system, Lifomic claims. These data can also help in creating a generative AI model to predict what features will be seen in a patient’s journey at any time. The combination of the recommended engine and the generative model provides an active view of what treatment options and when to consider.

In its infancy, XCures were started by human experts to manually train the model to extract the appropriate subset of data. Now, XCures is taking advantage of LifeOmic’s PrecisionOCR tool to automate and scale the process.

The clinical operations team identified and manually tagged relevant data points such as diagnosis, medications, omix, radiology reports, and any specific comorbidities that could affect treatment options. PreciscionOCR helps identify complex documents related to a large medical record, saving hours of experts’ manual effort while narrowing the pages of interest.

According to Lifeomics, the partnership highlights how healthcare companies are combining their expertise and their data processes to solve some of the industry’s most challenging problems.

Venturebeat’s mission Digital Town Square is set to become a place for technical decision makers to gain knowledge about the changing enterprise technology and practices. Learn more about membership.

Similar Posts

Leave a Reply

Your email address will not be published.